Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Becton Dickinson ( (BDX) ) has provided an announcement.
On February 5, 2025, BD announced its plan to separate its Biosciences and Diagnostic Solutions business from the rest of the company, aiming for completion by fiscal 2026, pending various approvals. In its fiscal 2025 first quarter results, BD reported strong financial performance with a revenue increase of 9.8% to $5.2 billion and EPS growth, alongside plans to unlock value through strategic separation and enhance its focus on innovation and growth in respective markets.
More about Becton Dickinson
BD (Becton, Dickinson and Company) is a leading global medical technology company that focuses on developing and providing innovative solutions in the medical field. The company offers a wide range of products and services, including medical devices, laboratory equipment, and diagnostic solutions, primarily serving healthcare institutions and systems worldwide.
YTD Price Performance: 7.03%
Average Trading Volume: 2,086,618
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $70.3B
Find detailed analytics on BDX stock on TipRanks’ Stock Analysis page.